News

This study will evaluate pharmacokinetics, safety and tolerability of DITEST in the target patient group of males with hypogonadism (Clinical Trials ID NCT02966652). Diurnal CEO Martin Whitaker said: "The

APL is a rare type of blood cancer that can kill within hours or days if it is not treated.  About 1,500 to 2,000 people in Europe are

The OPTICORE coating technology comprises two trigger systems and an accelerator to allow targeted drug release in the large intestine to improve local and/or systemic drug bioavailability. The inner

Under the terms of the agreement, Celgene committed $9 million to PharmAkea to extend the collaboration for 9 months. PharmAkea announced the original 3-year collaboration with Celgene in October

The phase 2 trial, dubbed Evolve, involved 14 patients ages 40 to 80 years who were undergoing percutaneous transluminal renal angioplasty and stenting. The study's endpoints were a change in

According to approval from the FDA’s Center for Biologics Evaluation and Research, the treatment can now be used among infants of six months or older. Before this approval,

CCH is marketed as XIAFLEX in the US and Xiapex in Europe. BioSpecifics' partner Endo International carried out the phase 2b trial, which enrolled 375 adult women with moderate or severe

The policy statement was informed by an FTC workshop held last year to examine how such drugs are marketed to consumers. The FTC also released its staff report

The financing from a single family office that is an existing investor includes the sale of a $1 million convertible note and up to $10 million in future equity